Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Weekly injection shows promise for boosting growth in teens with dwarfism

NCT ID NCT06732895

First seen Oct 31, 2025 · Last updated May 18, 2026 · Updated 24 times

Summary

This study tests a once-weekly injection called navepegritide in 24 adolescents (ages 12-18) with achondroplasia, the most common form of dwarfism. The goal is to see if it safely increases growth rate over 52 weeks compared to a placebo. The treatment aims to manage the condition by improving height, not cure it.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACHONDROPLASIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Ascendis Investigational Site

    RECRUITING

    Montreal, H3T 1C5, Canada

  • Ascendis Investigational Site

    RECRUITING

    Copenhagen, 2100, Denmark

  • Ascendis Investigational Site

    RECRUITING

    Paris, 75743, France

  • Ascendis Investigational Site

    RECRUITING

    Dublin, D01 YC76, Ireland

  • Ascendis Investigational Site

    RECRUITING

    Norwich, NR4 7UY, United Kingdom

Conditions

Explore the condition pages connected to this study.